{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-077821","form_type":"8-K","ticker":"PTGX","cik":"0001377121","company_name":"Protagonist Therapeutics, Inc","filed_at":"2023-07-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.739816+00:00","generated_at":"2026-06-13T12:37:28.119716+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Protagonist: Ph2 REVIVE hits primary endpoint (p=0.0003); Ph3 VERIFY enrollment completion expected 1Q 2024","bullets":["Phase 2b FRONTIER 1 trial of JNJ-2113 in moderate-to-severe psoriasis completed; Phase 3 psoriasis study initiation planned.","Enrollment completion for Phase 3 VERIFY trial of rusfertide in polycythemia vera expected in 1Q 2024.","Phase 2 REVIVE study met primary endpoint with high statistical significance (p=0.0003); 69.2% responders vs 18.5% placebo.","Rusfertide showed rapid hematocrit control in PACIFIC study; safety profile generally well tolerated with no new signals.","New Phase 2b study of JNJ-2113 in ulcerative colitis planned for 4Q 2023; cash runway through end of 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-077821","json":"https://secwatch.observer/filing/0001104659-23-077821.json","markdown":"https://secwatch.observer/filing/0001104659-23-077821.md","text":"https://secwatch.observer/filing/0001104659-23-077821.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1377121/000110465923077821/0001104659-23-077821-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1377121/000110465923077821/tm2320477d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T12:37:28.119716+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}